I had never heard about Viking Therapeutics (NASDAQ: VKTX ) until I got interested in drug obesity stocks, which had happened very recently. Since then, I broke down Novo Nordisk (I’m passionate about finance and investing, focusing on business analysis, fundamental analysis, valuation, and long-term growth, especially in sectors like AI, fintech, finance and tech. I study finance and economy and have hands-on experience in equity research, financial modeling, and creating investment content. I actively ana ...